The Orphan Drug Act has opened the door to almost unlimited price tags for drugs to treat rare diseases — burdening insurers, government programs, and families for whom obtaining the medication is often a matter of life and death.

The system intended to help those with rare diseases is being manipulated by drugmakers to maximize profits and to protect niche markets for medicines that millions of people already take — and it’s all legal.

Tensions mount as Trump considers candidates for top health positions, a documentary highlights the overlap between autism and gender dysphoria, and ‘citation cartels’ are gaming the publication system.

If the ACA is repealed, it could mean loss of coverage for several surprising health provisions, including therapy for children with autism, breast-feeding support for working mothers and assistance with emergency room visits.

A merger between nonprofit California Integrated Data Exchange and the Inland Empire Health Information Exchange could lead to the pooling of medical records of 16.7 million people in California.

Autism researchers in the United Kingdom fear that the country’s exit from the European Union will cut funding, scare away talent and strain partnerships.

The 21st Century Cures Act, having passed the U.S. Senate, now goes to President Barack Obama, who has promised to sign it.

A sprawling health bill expected to pass the U.S. Senate and become law before the end of the year is a grab bag for industries that spent plenty of money lobbying to make sure it happened that way.

Scientists are nervous about the next four years, grant money is making preprints more common, and researchers should grab a beer with a science writer.

More than 1,455 lobbyists representing 400 companies, universities and other organizations have pushed for or against an earlier House version of the 21st Century Cures bill.